After 62 years of regulating immunity, dexamethasone meets COVID-19
- PMID: 32778829
- PMCID: PMC7416654
- DOI: 10.1038/s41577-020-00421-x
After 62 years of regulating immunity, dexamethasone meets COVID-19
Abstract
Six months into the COVID-19 pandemic, effective treatments have been frustratingly sparse. The RECOVERY clinical trial, however, revealed that treatment with dexamethasone, a classic synthetic glucocorticoid, enhanced survival of critically ill patients with COVID-19. In this Comment, we discuss the immunological impacts of glucocorticoid therapy for COVID-19.
Conflict of interest statement
The authors declare no competing interests.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
